286 related articles for article (PubMed ID: 21769889)
1. Proteins from Erwinia asparaginase Erwinase ® and E. coli asparaginase 2 MEDAC ® for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear.
Bae N; Pollak A; Lubec G
Electrophoresis; 2011 Jul; 32(14):1824-8. PubMed ID: 21769889
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
3. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
5. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
[TBL] [Abstract][Full Text] [Related]
7. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
Boos J; Werber G; Ahlke E; Schulze-Westhoff P; Nowak-Göttl U; Würthwein G; Verspohl EJ; Ritter J; Jürgens H
Eur J Cancer; 1996 Aug; 32A(9):1544-50. PubMed ID: 8911116
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
11. Structural and functional insights into Erwinia carotovora L-asparaginase.
Papageorgiou AC; Posypanova GA; Andersson CS; Sokolov NN; Krasotkina J
FEBS J; 2008 Sep; 275(17):4306-16. PubMed ID: 18647344
[TBL] [Abstract][Full Text] [Related]
12. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
Rizzari C; Zucchetti M; Conter V; Diomede L; Bruno A; Gavazzi L; Paganini M; Sparano P; Lo Nigro L; Aricò M; Milani M; D'Incalci M
Ann Oncol; 2000 Feb; 11(2):189-93. PubMed ID: 10761754
[TBL] [Abstract][Full Text] [Related]
13. L-Asparaginase from Erwinia Chrysanthemi 3937: cloning, expression and characterization.
Kotzia GA; Labrou NE
J Biotechnol; 2007 Jan; 127(4):657-69. PubMed ID: 16984804
[TBL] [Abstract][Full Text] [Related]
14. [Bacterial L-asparaginase and glutamin(asparagin)ase: some properties, structure and anti-tumor activity].
Sokolov NN; Zanin VA; Aleksandrova SS
Vopr Med Khim; 2000; 46(6):531-48. PubMed ID: 11234278
[TBL] [Abstract][Full Text] [Related]
15. Cloning, expression and characterisation of Erwinia carotovora L-asparaginase.
Kotzia GA; Labrou NE
J Biotechnol; 2005 Oct; 119(4):309-23. PubMed ID: 15951039
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of native Escherichia coli asparaginase.
Borghorst S; Pieters R; Kuehnel HJ; Boos J; Hempel G
Pediatr Hematol Oncol; 2012 Mar; 29(2):154-65. PubMed ID: 22376019
[TBL] [Abstract][Full Text] [Related]
17. Monolith and coating enzymatic microreactors of L-asparaginase: kinetics study by MCE-LIF for potential application in acute lymphoblastic leukemia (ALL) treatment.
Qiao J; Qi L; Mu X; Chen Y
Analyst; 2011 May; 136(10):2077-83. PubMed ID: 21461410
[TBL] [Abstract][Full Text] [Related]
18. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
19. Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Salzer W; Seibel N; Smith M
Expert Opin Biol Ther; 2012 Oct; 12(10):1407-14. PubMed ID: 22946493
[TBL] [Abstract][Full Text] [Related]
20. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
